NCT06678074 - Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 6, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

September 1, 2026

Conditions

STEMISTEMI (ST Elevation MI)STEMI - ST Elevation Myocardial Infarction (MI)Stent Implantation

Interventions

DRUG

Atibuclimab (IC14), 20 mg/kg intravenously, once

monoclonal antibody against CD14

OTHER

Placebo, 150 mL intravenously, once

sterile normal saline for injection

Trial Locations (2)

RECRUITING

Washington University School of Medicine, St Louis

RECRUITING

University of Virginia, Charlottesville